PolyPid (NASDAQ:PYPD) Lowered to Sell Rating by Wall Street Zen

PolyPid (NASDAQ:PYPD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research analysts have also weighed in on PYPD. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Roth Mkm reduced their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Price Performance

PolyPid stock opened at $4.25 on Friday. The stock has a market capitalization of $81.09 million, a P/E ratio of -1.88 and a beta of 1.52. PolyPid has a 12-month low of $2.30 and a 12-month high of $5.12. The firm’s 50-day moving average is $4.44 and its two-hundred day moving average is $3.87.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). As a group, analysts forecast that PolyPid will post -1.79 EPS for the current year.

Institutional Trading of PolyPid

A number of institutional investors have recently modified their holdings of PYPD. AIGH Capital Management LLC increased its position in PolyPid by 26.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after purchasing an additional 277,844 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of PolyPid in the fourth quarter worth $451,000. Lumbard & Kellner LLC purchased a new position in shares of PolyPid in the 2nd quarter valued at $135,000. XTX Topco Ltd lifted its holdings in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of PolyPid during the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.